Literature DB >> 33769211

Pembrolizumab for choroidal metastases from non-small cell lung cancer: a case report and literature review.

Xinsheng Li1, Ya Liang1, Jingfan Wang1, Zizhong Hu1, Zhi-Lan Yuan1, Ping Xie1.   

Abstract

We described a 65-year-old male with choroidal metastases (CM) from non-small cell lung cancer (NSCLC). Pembrolizumab (Keytruda) combined with pemetrexed and capecitabine achieved excellent outcomes. After two cycles of pembrolizumab and chemotherapy, blurred vision and left eye pain were significantly relieved. Imaging and ophthalmologic examinations demonstrated complete resolution of the CM, as well as reduction of pulmonary shadow. CM from NSCLC shows complete and durable response to pembrolizumab and chemotherapy. We suggesting that immunotherapy combined with chemotherapy is a promising treatment for CM from NSCLC.

Entities:  

Keywords:  Immunotherapy; choroidal metastases; non-small cell lung cancer; pembrolizumab

Mesh：

Substances：

Year:  2021        PMID： 33769211      PMCID： PMC8475568          DOI： 10.1080/21645515.2021.1885282

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  15 in total

Review 1.  Pembrolizumab (Keytruda).

Authors:  Gerry Kwok; Thomas C C Yau; Joanne W Chiu; Eric Tse; Yok-Lam Kwong
Journal:  Hum Vaccin Immunother       Date:  2016-07-11       Impact factor: 3.452

Review 2.  The inner blood-retinal barrier: Cellular basis and development.

Authors:  Mónica Díaz-Coránguez; Carla Ramos; David A Antonetti
Journal:  Vision Res       Date:  2017-06-27       Impact factor: 1.886

3.  Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

Authors:  Leena Gandhi; Delvys Rodríguez-Abreu; Shirish Gadgeel; Emilio Esteban; Enriqueta Felip; Flávia De Angelis; Manuel Domine; Philip Clingan; Maximilian J Hochmair; Steven F Powell; Susanna Y-S Cheng; Helge G Bischoff; Nir Peled; Francesco Grossi; Ross R Jennens; Martin Reck; Rina Hui; Edward B Garon; Michael Boyer; Belén Rubio-Viqueira; Silvia Novello; Takayasu Kurata; Jhanelle E Gray; John Vida; Ziwen Wei; Jing Yang; Harry Raftopoulos; M Catherine Pietanza; Marina C Garassino
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

Review 4.  The seed and soil hypothesis revisited--the role of tumor-stroma interactions in metastasis to different organs.

Authors:  Robert R Langley; Isaiah J Fidler
Journal:  Int J Cancer       Date:  2011-03-25       Impact factor: 7.396

5.  Carcinoma metastatic to the eye and orbit. I. A clinicopathologic study of 227 cases.

Authors:  A P Ferry; R L Font
Journal:  Arch Ophthalmol       Date:  1974-10

6.  Survey of 520 eyes with uveal metastases.

Authors:  C L Shields; J A Shields; N E Gross; G P Schwartz; S E Lally
Journal:  Ophthalmology       Date:  1997-08       Impact factor: 12.079

7.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

8.  TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma.

Authors:  Jérôme Biton; Audrey Mansuet-Lupo; Nicolas Pécuchet; Marco Alifano; Hanane Ouakrim; Jennifer Arrondeau; Pascaline Boudou-Rouquette; François Goldwasser; Karen Leroy; Jeremy Goc; Marie Wislez; Claire Germain; Pierre Laurent-Puig; Marie-Caroline Dieu-Nosjean; Isabelle Cremer; Ronald Herbst; Hélène Blons; Diane Damotte
Journal:  Clin Cancer Res       Date:  2018-05-15       Impact factor: 12.531

Review 9.  PD-1 and its ligands in tolerance and immunity.

Authors:  Mary E Keir; Manish J Butte; Gordon J Freeman; Arlene H Sharpe
Journal:  Annu Rev Immunol       Date:  2008       Impact factor: 28.527

Review 10.  Choroidal metastases: origin, features, and therapy.

Authors:  Sruthi Arepalli; Swathi Kaliki; Carol L Shields
Journal:  Indian J Ophthalmol       Date:  2015-02       Impact factor: 1.848
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.